SLC2A1 and cancer: Glucose transporter 1 (GLUT1), a classic example of a glucose transporter, is universally overexpressed in cancer cells.[9b] Targeting GLUT1 to block glucose transport has proven effective in both preclinical and clinical studies.[9, 11] Therefore, dual‐pathway glycolysis inhibition by blocking upstream glucose supply while inhibiting downstream key enzyme activity might be a powerful and promising strategy for boosting energy deprivation of tumor cells.